Back
Ascentage Pharma Group International Co., Ltd. 10K Form
Sell
36
AAPG
Ascentage Pharma Group International Co., Ltd.
Last Price:
$23.52
Seasonality Move:
59.09%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive AAPG News And Ratings
See the #1 stock for the next 7 days that we like better than AAPG
AAPG Financial Statistics
Sales & Book Value
| Annual Sales: | $136.3M |
|---|---|
| Cash Flow: | $0 |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.46 |
| Price / Book: | 96.71 |
Profitability
| EPS (TTM): | -2.01260 |
|---|---|
| Net Income (TTM): | $-160.6M |
| Gross Margin: | $120.4M |
| Return on Equity: | -109.51% |
| Return on Assets: | -14.84% |
Ascentage Pharma Group International Co., Ltd. Earnings Forecast
Key Ascentage Pharma Group International Co., Ltd. Financial Ratios
-
The Gross Profit Margin over the past 9 years for AAPG is 88.39%.
-
The Selling, General & Administrative Expenses for AAPG have been equal to 39.07% of Gross Profit Margin.
-
The Research & Development expenses have been 93.18% of Revenue.
-
The Net Earning history of AAPG is -41.37% of Total Revenues.
-
Per Share Earnings over the last 9 years have been positive in 3 years.
Ascentage Pharma Group International Co., Ltd. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | AAPG |
| Website: | ascentage.com |
Debt
| Debt-to-Equity Ratio: | 6.2 |
|---|---|
| Current Ratio: | 1.26 |
| Quick Ratio: | 1.26 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 49.97 |
AAPG Technical Analysis vs Fundamental Analysis
Sell
36
Ascentage Pharma Group International Co., Ltd. (AAPG)
is a Sell
Is Ascentage Pharma Group International Co., Ltd. a Buy or a Sell?
-
Ascentage Pharma Group International Co., Ltd. stock is rated a SellThe current Ascentage Pharma Group International Co., Ltd. [AAPG] share price is $24.43. The Score for AAPG is 36, which is 28% below its historic median score of 50, and infers higher risk than normal.